These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28290847)

  • 1. [Comparative Analysis of the Efficacy and Safety of Rosuvastatin and Original Rosuvastatin].
    Bart BY; Luchinkina EE; Gordeev IG; Arutyunov GP; Taratukhin On Behalf Of The Workgroup Of Paritet Trial EO
    Kardiologiia; 2016 Jun; 56(6):46-49. PubMed ID: 28290847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of a generic rosuvastatin in a real-world setting: prospective, observational clinical study in Lebanese patients.
    Betto M; Fares J; Saliba N; Ballout H
    Ann Saudi Med; 2017; 37(5):366-374. PubMed ID: 28988251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
    Strutt K; Caplan R; Hutchison H; Dane A; Blasetto J
    Circ J; 2004 Feb; 68(2):107-13. PubMed ID: 14745143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial.
    Obońska K; Kasprzak M; Sikora J; Obońska E; Racki K; Goździkiewicz N; Krintus M; Kubica J
    Trials; 2017 Jul; 18(1):316. PubMed ID: 28697767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial.
    Hong SJ; Jeong HS; Ahn JC; Cha DH; Won KH; Kim W; Cho SK; Kim SY; Yoo BS; Sung KC; Rha SW; Shin JH; Han KR; Chung WS; Hyon MS; Lee HC; Bae JH; Rhee MY; Kwan J; Jeon DW; Yoo KD; Kim HS
    Clin Ther; 2018 Feb; 40(2):226-241.e4. PubMed ID: 29402522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosuvastatin: a high-potency HMG-CoA reductase inhibitor.
    Lopez LM
    J Am Pharm Assoc (2003); 2005; 45(4):503-13. PubMed ID: 16128507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
    McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW;
    Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Achievement of specified lipid and high-sensitivity C-reactive protein levels with two statins in Chinese patients with hypercholesterolaemia.
    Ding C; Hu M; Wu YJ; Tomlinson B
    Lipids Health Dis; 2015 Sep; 14():107. PubMed ID: 26365713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial.
    Ballantyne CM; Miller E; Chitra R
    Clin Ther; 2004 Nov; 26(11):1855-64. PubMed ID: 15639697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
    Jones PH; Davidson MH; Kashyap ML; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
    Atherosclerosis; 2009 May; 204(1):208-15. PubMed ID: 18996523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
    Roth EM; Rosenson RS; Carlson DM; Fukumoto SM; Setze CM; Blasetto JW; Khurmi NS; Stolzenbach JC; Williams LA
    Cardiovasc Drugs Ther; 2010 Dec; 24(5-6):421-8. PubMed ID: 20953684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
    Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
    Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review and meta-analysis on the therapeutic equivalence of statins.
    Weng TC; Yang YH; Lin SJ; Tai SH
    J Clin Pharm Ther; 2010 Apr; 35(2):139-51. PubMed ID: 20456733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of two intensive statin regimens on progression of coronary disease.
    Nicholls SJ; Ballantyne CM; Barter PJ; Chapman MJ; Erbel RM; Libby P; Raichlen JS; Uno K; Borgman M; Wolski K; Nissen SE
    N Engl J Med; 2011 Dec; 365(22):2078-87. PubMed ID: 22085316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
    Farnier M; Jones P; Severance R; Averna M; Steinhagen-Thiessen E; Colhoun HM; Du Y; Hanotin C; Donahue S
    Atherosclerosis; 2016 Jan; 244():138-46. PubMed ID: 26638010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
    Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
    Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.